Blueprint Medicines (BPMC) Competitor Comparison
We are evaluating the key criteria listed to compare Blueprint Medicines (BPMC) against its competitors in the Biotechnology industry.
Market Capitalization
31 / 368Gross Profits
35 / 278Total Revenue
56 / 300EBITDA
323 / 337Free Cashflow
334 / 352Quick Ratio
229 / 357Earnings per Share
212 / 359Dividend yield
0 / 6Total Cash
40 / 358Performance 3 years
112 / 368Performance 5 years
101 / 368Performance 10 years
28 / 368Linearity 3 years
43 / 368Linearity 5 years
30 / 368Linearity 10 years
327 / 367Total Rank
274 / 368Dividend Rank
70 / 368Valuation Rank
191 / 368Piotroski Rank
27 / 368Muliplier Rank
298 / 368Market Capitalization - BPMC ranking 31 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.